Davis Polk advised the sole book-running manager in connection with the $215.6 million common stock offering of 6,900,000 shares of common stock of Editas Medicine, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “EDIT.”
Based in Cambridge, Massachusetts, Editas Medicine is a leading, clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases.
The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associate Andrew J. Terjesen. The intellectual property and technology transactions team included partner David R. Bauer and associates Christopher C. Woller and Hilary Smith. The tax team included partner Po Sit and associate Tomislava Dragicevic. All members of the Davis Polk team are based in the New York office.